Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma has appointed David Isserman as chief marketing officer of the company. Mr Isserman, who worked as a longtime consultant to the company, will be responsible for overseeing the company’s corporate communications and investor relations.
Subscribe to our email newsletter
Additionally, he will also work directly with Nutra Pharma licensees to coordinate ongoing marketing and outreach initiatives for the company’s drug pipeline, including its recently launched pain relievers, Cobroxin and Nyloxin.
Prior to Joining Nutra Pharma, Mr Isserman served as president of Isserman Consulting, and was a co-founder of RareShare. Over the past several years, Mr Isserman has served on several scientific and environmental non-profit boards and currently serves as a Trustee for the Academy of Science of St Louis.
Rik Deitsch, chairman and CEO of Nutra Pharma, said: “We are thrilled to welcome David to our executive management team as chief marketing officer. David’s extensive knowledge and experience in marketing communications and his work within the biotechnology industry will serve as tremendous assets to Nutra Pharma as we build our presence within the investment and scientific communities and as we extend the global reach of our drug brands, including Cobroxin and Nyloxin.”
David Isserman, said: “It has been a pleasure working with Nutra Pharma in a consulting role for the past several years and I am excited to now join the company in an official capacity as its chief marketing officer. I look forward to continuing to build awareness about Nutra Pharma, our recently launched pain relievers, Cobroxin and Nyloxin, and our important work developing novel treatments for neurologic and autoimmune disorders.”